What Amarin does

Amarin Corporation plc is an Ireland-domiciled, NASDAQ-listed (AMRN) biopharmaceutical company founded in 1989 that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl) — the first FDA-approved prescription therapy comprised solely of icosapent ethyl, a proprietary high-purity form of the omega-3 fatty acid eicosapentaenoic acid (EPA) derived from fish oil. The product is indicated for cardiovascular risk reduction as an adjunct to maximally tolerated statin therapy in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors, and is also approved for severe hypertriglyceridemia (≥500 mg/dL). Its clinical and commercial foundation is the landmark REDUCE-IT cardiovascular outcomes trial (8,179 patients, 400+ sites across 11 countries, ~4.9-year median follow-up) demonstrating a 25% reduction in major adverse cardiovascular events when added to statin therapy, supported by 500+ scientific publications and 70+ medical society recommendations. Regulatory approvals span 50+ countries with European IP protection extending to 2039.

Amarin operates a hybrid commercialization model. In the United States, a direct sales organization markets VASCEPA to cardiologists and high-prescribing physicians through national pharmacy benefit managers (generating $35.6M of Q1 2026 revenue, ~79% of total). Internationally, the company executes a fully-partnered distribution strategy covering approximately 100 markets via exclusive licensing and supply agreements with Recordati S.p.A. (Europe, June 2025 deal, 59 countries, $25M upfront), Eddingpharm (China, 2015, approved 2024), HLS Therapeutics (Canada, 2017), Lotus Pharmaceuticals (SE Asia/South Korea, 2023), Neopharm (Israel, 2023), and Vianex (Greece, 2024). Revenue streams include U.S. product sales, European product sales ($4.9M in Q1 2026), Rest-of-World product sales ($2.8M), and licensing/royalty income ($1.8M, up 84% YoY).

Following a global restructuring initiative targeting $70M in annualized savings ($39.6M realized through Q1 2026), Amarin reported two consecutive quarters of positive operating cash flow, holds $307.8M in cash and investments with no debt, and is exploring strategic alternatives with Barclays. Reported FY 2025 revenue of $213.6M (down 6.5% YoY) reflects ongoing U.S. pressure from generic competition, which was materially compounded by the June 2026 U.S. Supreme Court ruling in Hikma v. Amarin that Hikma's skinny-label generic icosapent ethyl does not infringe Amarin's patents.

Name

Amarin

Legal name

Amarin Corporation plc

Website

https://amarincorp.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

Amarin Corporation plc is an Ireland-domiciled biopharmaceutical company that develops and commercializes VASCEPA/VAZKEPA (icosapent ethyl), the first FDA-approved prescription EPA therapy for cardiovascular risk reduction in statin-treated patients with elevated triglycerides, sold via direct U.S. sales and partner networks across ~100 global markets.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industry

Omega-3 & Specialty Lipids (Fish/Algal Oils, EPA/DHA, MCTs, CLA, Phospholipids) (AFAJAKAC)

Keywords

• Cardiovascular pharmaceuticals
• Prescription omega-3 therapy
• Cardiovascular risk reduction
• Lipid management drugs
• Icosapent ethyl treatment

Headquarters

HQ city

Ballsbridge

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Revenue model

1. Product Sales - United States: Direct sales of VASCEPA in the U.S. market through Amarin's commercial organization. Revenue from national pharmacy benefit managers (PBMs) and direct prescriptions. Q1 2026 U.S. product revenue of $35.6 million.
2. Product Revenue - Europe: Revenue from VAZKEPA sales through European partners, particularly Recordati S.p.A. under exclusive licensing and supply agreement. Q1 2026 European product revenue of $4.9 million.
3. Licensing and Royalties: Revenue from international commercial partners including royalties from Eddingpharm (China), HLS Therapeutics (Canada), Lotus Pharmaceuticals (Southeast Asia), and other partners. Q1 2026 licensing and royalty revenue of $1.8 million, up 84% year-over-year.
4. Product Revenue - Rest of World: Revenue from international markets including Canada, China, Australia, Lebanon, UAE, Saudi Arabia, Qatar, Bahrain, and Kuwait. Q1 2026 ROW product revenue of $2.8 million.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

Amarin develops, manufactures, and commercializes VASCEPA/VAZKEPA (icosapent ethyl), a prescription-only omega-3 fatty acid (EPA) therapy approved as an adjunct to statin therapy to reduce cardiovascular events in high-risk patients with elevated triglycerides, and as adjunct to diet for severe hypertriglyceridemia. The company sells directly in the U.S. and through regional commercial partners across approximately 100 international markets.

Product overview

Amarin is a global pharmaceutical company with a single commercialized product - VASCEPA®/VAZKEPA® (icosapent ethyl). This is a unified product marketed under different brand names in different regions: VASCEPA® in the United States and other markets, and VAZKEPA® in Europe and the UK. The product is a prescription-only fish oil-derived medication (icosapent ethyl/EPA) approved for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and for severe hypertriglyceridemia. The company operates through direct sales in the U.S. and indirect distribution internationally through commercial partners, covering approximately 100 markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• VASCEPA/VAZKEPA (icosapent ethyl): Prescription cardiovascular drug (icosapent ethyl capsules) approved for reducing cardiovascular risk in high-risk patients with elevated triglycerides on statin therapy. Also approved for severe hypertriglyceridemia. Marketed as VASCEPA in the US and VAZKEPA in Europe and other markets.
• REDUCE-IT

Products and services

• VASCEPA/VAZKEPA (icosapent ethyl) Prescription-only medicine containing icosapent ethyl, a unique form of EPA (an omega-3 fatty acid derived from fish oil). Marketed as VASCEPA in the U.S. and VAZKEPA in Europe and other markets. Approved as an adjunct to maximally tolerated statin therapy to reduce cardiovascular risk in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes plus additional risk factors; and as adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL). Prescribed more than 25 million times globally.

Quantifiable outcome

• 25% reduction in major adverse cardiovascular events (MACE) compared to placebo when added to statin therapy
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, minor and major.

• Recordati S.p.A.coreChannel Partner/ Reseller/ Distributor · 1 June 2025Exclusive license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in Europe. Recordati is a leading international pharmaceutical group with consolidated net revenues of €2.6 billion in 2025. Recordati commenced commercial efforts in 10 countries including Italy (Q4 2025 launch) with plans to expand across Europe over several years. This partnership represents Amarin's fully-partnered international commercial strategy.
• VianexminorChannel Partner/ Reseller/ Distributor · 1 January 2024Partnership with Vianex for distribution and commercialization of VAZKEPA in Greece. Reimbursement secured in Greece in 2024.
• Lotus PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive long-term agreement to distribute and commercialize VAZKEPA across ten countries in Southeast Asia and South Korea, announced in 2023.
• NeopharmmajorChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive marketing and commercial agreement for VAZKEPA in Israel, announced in 2023. VAZKEPA approved in Israel in 2023.
• HLS TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 January 2017Agreement to commercialize VASCEPA in Canada, announced in 2017. HLS Therapeutics presents REDUCE-IT and EPA mechanistic data at Canadian Cardiovascular Congress and commercializes VASCEPA in Canada.
• EddingpharmcoreChannel Partner/ Reseller/ Distributor · 1 January 2015Agreement to develop and commercialize VASCEPA in China, announced in 2015. EddingPharm received regulatory approval for VASCEPA in mainland China for the cardiovascular risk reduction indication in 2024.
• BiologiminorChannel Partner/ Reseller/ DistributorRegional commercial partner for Australia. Biologi is listed among Amarin's trusted strategic partners.
• CSL SeqirusminorChannel Partner/ Reseller/ DistributorRegional commercial partner for Australia. CSL Seqirus is listed among Amarin's trusted strategic partners.
• Brigham and Women's HospitalcoreStrategic or Co-development PartnerResearch partner for REDUCE-IT trial. Dr. Deepak L. Bhatt serves as Chair of the REDUCE-IT Steering Committee with research funding paid to Brigham and Women's Hospital and the Icahn School of Medicine at Mount Sinai.
• Mount Sinai - Icahn School of MedicinecoreStrategic or Co-development PartnerAcademic partner for REDUCE-IT trial. Dr. Deepak L. Bhatt is Director of the Mount Sinai Fuster Heart Hospital and Principal Investigator of REDUCE-IT. Research funding paid to Icahn School of Medicine at Mount Sinai.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Esperion Therapeutics: Specialty pharma focused on lipid management with NEXLETOL/NEXLIZET (bempedoic acid) for LDL-C lowering in statin-treated patients. Targets the same cardiovascular residual-risk patient population as Amarin, with overlapping cardiology prescribers and similar commercial dynamics.
• Ionis Pharmaceuticals: Develops olezarsen (TRYNGOLZA) for familial chylomicronemia syndrome and severe hypertriglyceridemia — directly competing with VASCEPA in one of its approved indications. Ionis/AstraZeneca partnership provides commercial scale that Amarin lacks in international markets.

Emerging players

• NewAmsterdam Pharma: Late-stage clinical biotech developing obicetrapib, an oral CETP inhibitor for dyslipidemia. Targeting statin-treated patients with elevated CV risk — directly overlapping with Amarin's prescriber base and patient population in CV risk reduction.
• Arrowhead Pharmaceuticals: Clinical-stage company developing RNA interference therapeutics for cardiovascular and metabolic diseases, including plozasiran (APOC3) targeting severe hypertriglyceridemia. Competes in the same triglyceride-driven CV space as icosapent ethyl.
• Madrigal Pharmaceuticals: Specialty pharma with Rezdiffra (resmetirom) approved for MASH/NASH with significant fibrosis. Cardiovascular/metabolic specialty focus with overlapping physician call points in endocrinology and cardiology practices.
• Viking Therapeutics: Clinical-stage biotech developing metabolic and cardiovascular therapies, including VK2735 for obesity and oral formulations targeting cardiometabolic disease. Emerging competitor in adjacent CV/metabolic therapeutic categories.

Broad incumbents

• Amgen: Global biopharmaceutical incumbent with Repatha (evolocumab), a leading PCSK9 inhibitor for LDL-C lowering. Competes with Amarin in cardiovascular lipid management through different mechanism but overlapping prescriber base and patient population.
• Novartis: Large incumbent with Leqvio (inclisiran), an siRNA therapy for LDL-C lowering in cardiovascular patients. Represents a meaningful alternative therapeutic approach in the lipid management space where Amarin competes for prescriber attention and guideline inclusion.
• Sanofi: Global pharma incumbent with Praluent (alirocumab, partnered with Regeneron), a PCSK9 inhibitor. Competes in cardiovascular lipid management with established cardiology commercial infrastructure across all major markets including Europe and Asia.
• Pfizer: Largest pharmaceutical incumbent with legacy Lipitor franchise and broader cardiovascular portfolio. Provides scale benchmark and potential acquirer profile, while competing in the broader lipid management and CV risk reduction market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/amarincorp
• YouTubeyoutube.com/channel/UCwCpDSyA916KdUnSDqk8Mfw
• LinkedInlinkedin.com/company/amarin-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amarin